Fundz
Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →

Yarrow Bioscience completes merger with VYNE Therapeutics

PUBLIC · YARWJul 27, 2026•14 days ago

Acquiring Company

Yarrow Bioscience

Acquired Company

VYNE Therapeutics

United StatesBridgewaterBiotechnologyHealth CareTherapeuticsHealthcare

Description

Yarrow Bioscience has successfully completed its merger with VYNE Therapeutics. Following the merger, the combined entity will continue under the Yarrow Bioscience name and will initiate dosing in a Phase 2a/2b trial for YB-101. The merger included private financings totaling approximately $200 million.

Company Information

Company

Yarrow Bioscience

Location

United States

About

Yarrow Bioscience, Inc. is a biotechnology company focused on developing novel therapies for autoimmune diseases. Founded by RTW Investments, Yarrow is advancing its lead program, YB-101, which targets thyroid-stimulating hormone receptors for the treatment of Graves' disease and thyroid eye disease. The company aims to address significant unmet needs in these therapeutic areas.

Related People

Choose your plan to reveal verified contacts

Predictive Intelligence
Strategic

ML-powered predictions for Yarrow Bioscience's next move

Learn about Strategic plan

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed

Frequently asked

Who acquired VYNE Therapeutics?

VYNE Therapeutics was acquired by Yarrow Bioscience, based in United States. The deal was reported on July 27, 2026. Yarrow Bioscience, Inc. is a biotechnology company focused on developing novel therapies for autoimmune diseases. Yarrow Bioscience is publicly traded (YARW) and operates in Biotechnology.

When did Yarrow Bioscience acquire VYNE Therapeutics?

Yarrow Bioscience's acquisition of VYNE Therapeutics was reported on July 27, 2026. Yarrow Bioscience has successfully completed its merger with VYNE Therapeutics. Following the merger, the combined entity will continue under the Yarrow Bioscience name and will initiate dosing in a Phase 2a/2b trial for YB-101. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does VYNE Therapeutics do?

It is publicly traded (YARW), operating in Healthcare, and is based in Bridgewater.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.